3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Gynecologic
1
Conditions
Ovarian Neoplasms
4
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Turcot syndrome
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Gynecologic Cancers
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
5
Nivolumab
2
tislelizumab
1
sintilimab
1
durvalumab
1
dostarlimab
1
denileukin diftitox
1
avelumab
1
atezolizumab
1
Taxes
1
Paclitaxel
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Interleukin-2
1
Immune Checkpoint Inhibitors
1
E7777 fusion protein
1
Docetaxel
1
Carboplatin
1
Biopsy
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
Immune Checkpoint Inhibitors
×
Gynecologic
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled